War against NRAS-Mutant Melanoma Using Targeted Therapies Remains Challenging.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 35587446.
- Also identified by DOI 10.1158/1078-0432.CCR-22-1256.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the search for targeting MAPK plus other pathways in NRAS-mutant melanoma, a phase Ib/II trial tested binimetinib plus ribociclib in metastatic melanoma. The response rate in the phase II trial was 19.5%, and the median progression-free survival was 3.7 months. See related article by Schuler et al., p. 3002.
Medical subject headings
- Melanoma
- Protein Kinase Inhibitors